Febraayo 2023: Oggolaanshaha degdega ah waxaa siisay FDA pirtobrutinib (Jaypirca, Eli Lilly iyo Company) ee lymphoma unugga mantle ee soo noqnoqda ama soo noqnoqda.
Gudaha BRUIN (NCT03740529), calaamad furan, xarun badan, tijaabo hal cudud ah oo ku saabsan monotherapy pirtobrutinib oo ka kooban 120 bukaan oo MCL ah kuwaas oo horey u helay daaweynta BTK inhibitor, waxtarka ayaa la qiimeeyay. Bukaan-socodka ayaa horey u helay dhexdhexaad saddex xariiq oo daawaynta ah, iyadoo 93% ay heleen laba ama ka badan. Ibrutinib (67%), acalabrutinib (30%), iyo zanubrutinib (8%), kuwaas oo ahaa kuwa ugu badan ee loo qoro ka hor BTK inhibitors, ayaa la joojiyay 83% bukaanada sababtoo ah cudurro ka soo horjeeda ama ka sii daraya. Pirtobrutinib ayaa afka laga siiyay hal mar maalintii iyadoo la eegayo qiyaasta 200 mg oo la sii waday ilaa uu cudurku ka sii socdo ama waxyeellooyinka ay noqdeen kuwo aan loo dulqaadan karin.
Heerka jawaabta guud (ORR) iyo muddada jawaabta (DOR), sida ay go'aamiyeen guddiga dib u eegista madax-bannaan ee isticmaalaya shuruudaha Lugano, ayaa ahaa tallaabooyinka ugu horreeya ee waxtarka leh. ORR wuxuu ahaa 50% (95% CI: 41, 59) iyo 13% jawaab bixiyaasha ayaa si buuxda u dhamaystiray sahanka. Qiyaasta qiyaasta DOR ee bilaha 6 ayaa lagu qiyaasay 65.3% (95% CI: 49.8, 77.1), iyo qiyaasta dhexdhexaadka ah ee DOR waxay ahayd 8.3 bilood (95% CI: 5.7, NE).
Bukaannada qaba MCL, daal, raaxo la'aanta muruqyada, shubanka, edoema, dyspnea, oof-wareen, iyo nabarro ayaa ahaa waxyeellooyinka soo noqnoqda (15%). Hoos-u-dhaca neutrophils, lymphocyte, iyo tirooyinka platelet waxay ahaayeen fasalka 3 ama 4 cilladaha shaybaarka ee 10% shakhsiyaadka. Ka-hortagga iyo digniinaha ku saabsan caabuqyada, dhiig-baxa, cytopenia, fibrillation atrial iyo flutter, iyo malignant-ka labaad ee ugu weyn ayaa lagu daray alaabta lagu qoray.
Waxaa lagula talinayaa in la qaato 200 mg of pirtobrutinib hal mar maalintii ilaa uu cudurku ka sii socdo ama ay suntu noqoto mid aan loo dulqaadan karin.
